Legal group William Fry has appointed Lyn Brennan as a partner to its banking and finance division.
This builds on the group’s 2018 partner appointments of Padraig Kinsella and Jason Hollis, in addition to the appointment of Eoghan O‘Tuama as head of Listings.
Ms Brennan joins William Fry from Milbank, Tweed, Hadley & McCloy LLP in New York where she has worked for the last four years.
Over this time she gained experience in the financial services sector, with particular focus on leveraged finance, representing US and international corporates, banks and other financial institutions.
Prior to this, Ms Brennan was based in Dublin working with A&L Goodbody and McCann FitzGerald.
“I am delighted to announce that Lyn will be joining our market leading banking & finance practice,” Rachel Stanton, head of banking & finance at William Fry, said.
“This is an exciting appointment and one that will enable us to continue to grow.”
Elsewhere UDG Healthcare has appointed Peter Chambre and Shane Cooke as non-executive directors of the company with effect from next month.
Mr Chambre has held senior positions in the pharmaceutical and life sciences sectors and has been a director of a number of international public and private companies.
He is currently chairman of Immatics Biotechnologies, a clinical stage cancer immunotherapy company based in Germany and the United States.
Mr Chambre is also a trustee of Cancer Research UK since 2016 and has chaired Cancer Research Technology, the charity‘s commercialisation division since 2011.
Prior to this, he held the position of CEO of Cambridge Antibody Group until 2006. More recently, he was a non-executive director of Spectris until December 2016, and of Touchstone Innovations until January 2017.
Mr Cooke meanwhile has experience in the pharmaceutical and life sciences sectors in both Europe and the United States and is currently a non-executive director of NASDAQ-listed Alkermes, having previously held the position of president from September 2011 until his retirement in March 2018.
Prior to this, he spent 10 years as CFO of Elan from 2001, and from 2007 he also was head of Elan Drug Technologies.
He currently also serves as a non-executive director on the board of Prothena Corporation, and of Endo International.
Commenting on both appointments, Peter Gray, chairman of UDG Healthcare, said: “We‘re delighted to welcome Peter and Shane to the board, each of whom bring extensive experience with European and US healthcare companies on both the service provision and service procurement sides.”
“Their insights will further inform our continued strategic development of the group.”